DS1025 enters clinical development for advanced solid tumors
DS1025 is entering clinical development for patients with advanced solid tumors as a CD25-directed ADC.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
DS1025 is entering clinical development for patients with advanced solid tumors as a CD25-directed ADC.